[Smoking cessation in patients with lung cancer].
Smoking cessation is an important part of the management of patients with lung cancer. Continued smoking has been found to diminish treatment efficacy, to exacerbate side effects and to have a detrimental effect on survival. Smoking increases postoperative pulmonary complications and tolerance and efficacy of medical treatment (chemotherapy, targeted therapy, radiotherapy) are diminished. Moreover, the quality of life of current smokers is lower and the risk of a second primary malignancy is increased. Hospitalization is a good opportunity to propose smoking cessation. Clinical practice guidelines recommend the use of combined behavioral and pharmacological therapies. The efficacy of smoking cessation programs for cancer patients has been demonstrated. There is a clear dose-response relationship between number of contacts, intensity level of person-to-person contact and total amount of contact time. Multidisciplinary approaches increase abstinence rates. First line phamacotherapies (nicotine replacement therapy and sustained-release antidepressant bupropion) have been found to be safe and effective. Varenicline is a new drug for smoking cessation but it remains to be evaluated in oncology patients.
Quantin
X
X
Service des maladies respiratoires, Hôpital A de Villeneuve, CHU de Montpellier, Montpelier cedex, France. x-quantin@chu-montpellier.fr
Stoebner-Delbarre
A
A
Guichenez
P
P
Pujol
J-L
JL
D006801:Humans; D008175:Lung Neoplasms / Q000209:etiology / Q000628:therapy; D012907:Smoking / Q000009:adverse effects; D016540:Smoking Cessation / Q000379:methods*